Canopy Growth tanks on Q4 results: ‘achieving profitability is critical’
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
May 27, 2022
The cannabis company expects to turn adjusted EBITDA positive in FY24.
The Nasdaq-listed shares of the Canadian firm are down 20% on Friday.
Shares of Canopy Growth Corp (NASDAQ: CGC) are down nearly 20% on Friday after the cannabis company reported its fourth-quarter results that came in shy of Wall Street expectations.
Notable figures in Canopy Growth Q4 results
Lost C$574.6 million in Q4 versus the year-ago figure of C$700 million.Per-share loss of C$1.46 was much narrower than last year’s C$1.85.Revenue tanked 25% to C$126.1 million, as per the earnings press release.Consensus was for 30 cents of per-share loss on C$129.9 million in revenue.Reported gross margin climbed sharply from 7.0% to 142% on YoY basis.
Cash and short-term investments were down C$0.9 billion to C$1.40 billion. In the earnings press release, CEO David Klein said:
Are you looking for fast-news, hot-tips and market analysis?
Sign-up for the Invezz newsletter, today.
In the fiscal year ahead, we will remain focused on growing our market share in the key segments that will drive profitable growth and continuing to scale our premium brands across North America.
Canopy Growth is committed to profitability
Canopy Growth expects to turn adjusted EBITDA positive in fiscal 2024, excluding its U.S. THC businesses and investments in BioSteel drinks. As per CFO Judy Hong:
Achieving profitability is critical and we have undertaken additional initiatives to streamline and drive efficiencies for our global cannabis business. In FY23, we’re focused on executing our path to profitability in Canada.
The stock is now down 50% for the year.
68% of retail CFD accounts lose money
Health & pharmaceuticals
Stocks & Shares